| Autor: |
William G. Henderson, Gulshan K. Sethi, Vladimir Curcovic, Thomas Raya, Stuart Pett, Charles Barbiere, John C. Lucke, Kodangudi Ramanathan, David C. Booth, Daniel W. Lewis, J. David Talley, Valdimir Birjiniuk, Clive Robinson, Tamim Antckli, Mitchell W. Krucoff, Rick A. Esposito, Sarah Vernon, Frederick L. Grover, Darryl Weiman, Francis Duhaylongsod, Edward Murphy, Douglass A. Morrison, Harkness Floten, Jerome Sacks, Steven P. Sedlis |
| Rok vydání: |
1999 |
| Předmět: |
|
| Zdroj: |
Controlled Clinical Trials. 20:601-619 |
| ISSN: |
0197-2456 |
| DOI: |
10.1016/s0197-2456(99)00033-1 |
| Popis: |
This multicenter, prospective randomized trial was designed to test the hypotheses that percutaneous coronary intervention (PCI) is a safe and effective alternative to coronary artery bypass grafting (CABG) for patients with refractory ischemia and high risk of adverse outcomes. As a comparison of revascularization strategies, the trial specifically allows surgeons and interventionists to use new techniques as they become clinically available. After 42 months of this 72-month trial, 17,624 patients have been screened and 2022 met eligibility requirements: 341 have been randomized to either CABG or PCI, and the remaining 1681 are being prospectively followed in a registry. The 3-year overall survival of patients in the registry and randomized trial is comparable. To enhance accrual into the randomized trial, site visits were conducted, a few low-accruing hospitals were put on probation and/or replaced, eligibility criteria were reviewed at annual meetings of investigators, and the accrual period was extended by 1 year. These data demonstrate that a prospective randomized trial and registry of coronary revascularization for medically refractory high-risk patients is feasible. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect